JP2017512063A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512063A5
JP2017512063A5 JP2016555527A JP2016555527A JP2017512063A5 JP 2017512063 A5 JP2017512063 A5 JP 2017512063A5 JP 2016555527 A JP2016555527 A JP 2016555527A JP 2016555527 A JP2016555527 A JP 2016555527A JP 2017512063 A5 JP2017512063 A5 JP 2017512063A5
Authority
JP
Japan
Prior art keywords
fusion protein
residue
multimeric fusion
region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555527A
Other languages
English (en)
Japanese (ja)
Other versions
JP6851200B2 (ja
JP2017512063A (ja
Filing date
Publication date
Priority claimed from GB201403913A external-priority patent/GB201403913D0/en
Priority claimed from GB201403912A external-priority patent/GB201403912D0/en
Priority claimed from GB201405952A external-priority patent/GB201405952D0/en
Priority claimed from GB201412646A external-priority patent/GB201412646D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/054687 external-priority patent/WO2015132364A1/en
Publication of JP2017512063A publication Critical patent/JP2017512063A/ja
Publication of JP2017512063A5 publication Critical patent/JP2017512063A5/ja
Application granted granted Critical
Publication of JP6851200B2 publication Critical patent/JP6851200B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555527A 2014-03-05 2015-03-05 多量体Fcタンパク質 Expired - Fee Related JP6851200B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB201403913A GB201403913D0 (en) 2014-03-05 2014-03-05 Proteins
GB201403912A GB201403912D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403913.5 2014-03-05
GB1403912.7 2014-03-05
GB201405952A GB201405952D0 (en) 2014-04-02 2014-04-02 Proteins
GB1405952.1 2014-04-02
GB201412646A GB201412646D0 (en) 2014-07-16 2014-07-16 Proteins
GB1412646.0 2014-07-16
PCT/EP2015/054687 WO2015132364A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (3)

Publication Number Publication Date
JP2017512063A JP2017512063A (ja) 2017-05-18
JP2017512063A5 true JP2017512063A5 (OSRAM) 2018-04-12
JP6851200B2 JP6851200B2 (ja) 2021-03-31

Family

ID=52629578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555527A Expired - Fee Related JP6851200B2 (ja) 2014-03-05 2015-03-05 多量体Fcタンパク質

Country Status (15)

Country Link
US (1) US11352414B2 (OSRAM)
EP (1) EP3114143B1 (OSRAM)
JP (1) JP6851200B2 (OSRAM)
KR (1) KR20160130463A (OSRAM)
CN (1) CN106068274A (OSRAM)
AU (1) AU2015226100B2 (OSRAM)
BR (1) BR112016020368A2 (OSRAM)
CA (1) CA2939198A1 (OSRAM)
IL (1) IL247096A0 (OSRAM)
MX (1) MX2016010951A (OSRAM)
RU (1) RU2016139006A (OSRAM)
SG (1) SG11201606597QA (OSRAM)
TW (1) TW201619188A (OSRAM)
UY (1) UY36021A (OSRAM)
WO (1) WO2015132364A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
CN106661125B (zh) 2014-05-02 2021-10-01 动量制药公司 涉及工程化Fc构建体的组合物和方法
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
MX394116B (es) 2015-07-24 2025-03-19 Gliknik Inc Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
CA3012037A1 (en) * 2016-01-27 2017-08-03 Csl Behring Recombinant Facility Ag Recombinant igg fc multimers
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
KR102635635B1 (ko) 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
CN109641048A (zh) 2016-07-22 2019-04-16 格利克尼克股份有限公司 产生具有增强的Fc受体结合的经有序多聚化的免疫球蛋白Fc组合物的人蛋白片段的融合蛋白
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
AU2017371182B2 (en) 2016-12-09 2024-03-28 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
CN113336849A (zh) 2017-03-28 2021-09-03 礼进生物医药科技(上海)有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
WO2018185131A2 (en) 2017-04-05 2018-10-11 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
KR101913743B1 (ko) 2017-04-07 2018-11-01 국민대학교 산학협력단 혈중 반감기 연장을 위한 항체 Fc 변이체들
BR112019025583A2 (pt) * 2017-06-05 2020-06-16 Janssen Biotech, Inc. Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3
CA3085385A1 (en) * 2017-12-14 2019-06-20 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of neuromyelitis optica
WO2019175605A1 (en) * 2018-03-16 2019-09-19 Liverpool School Of Tropical Medicine Chimeric fc receptor binding proteins and uses thereof
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CN113271972B (zh) * 2018-11-14 2025-06-17 Jn生物科学有限责任公司 用于替代IVIG的多聚体杂交Fc蛋白
KR20220062084A (ko) 2019-09-13 2022-05-13 체에스엘 베링 렝나우 아게 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체
JP2023505493A (ja) * 2019-12-06 2023-02-09 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Fc多量体の安定組成物
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业(上海)股份有限公司 一种cdc平台抗体
WO2023239940A1 (en) * 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6114515A (en) 1997-08-25 2000-09-05 Smithkline Beecham Corporation PIGRL-1, a member of immunoglobulin gene superfamily
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY129566A (en) 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US6475749B1 (en) 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Adcc活性を増強させた抗体及びその製造方法
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP2185589B1 (en) * 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
JP5604311B2 (ja) 2008-03-13 2014-10-08 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
AU2010206681A1 (en) 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013049254A1 (en) 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
JP6313712B2 (ja) 2011-12-21 2018-04-18 アムジエン・インコーポレーテツド 新生児Fc受容体への結合を強化された変異型Fcポリペプチド
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Fc 단편 유도체
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
EP2880057A4 (en) * 2012-08-02 2016-03-23 Jn Biosciences Llc MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
RU2015106812A (ru) 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
WO2014031646A2 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
CN110894231A (zh) 2012-10-17 2020-03-20 康诺贝林伦瑙有限公司 免疫调节蛋白
AU2015226101B2 (en) 2014-03-05 2019-08-22 Ucb Biopharma Sprl Multimeric Fc proteins
BR112016020368A2 (pt) * 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
AU2015248785A1 (en) 2014-04-16 2016-11-24 Ucb Biopharma Sprl Multimeric Fc proteins
CN106661125B (zh) 2014-05-02 2021-10-01 动量制药公司 涉及工程化Fc构建体的组合物和方法
EP3265131A1 (en) 2015-03-05 2018-01-10 UCB Biopharma SPRL Polymeric fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins

Similar Documents

Publication Publication Date Title
JP2017512063A5 (OSRAM)
JP2017509335A5 (OSRAM)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
JP2016526909A5 (OSRAM)
HRP20220080T1 (hr) Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin
JP2019522465A5 (OSRAM)
RU2016139006A (ru) Мультимерные fc-белки
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
JP2016525100A5 (OSRAM)
RU2013140685A (ru) ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
MX2009012319A (es) Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
JP2020500015A5 (OSRAM)
JP2019516665A5 (OSRAM)
JP2014506790A5 (OSRAM)
JP2005120106A5 (OSRAM)
RU2018138703A (ru) Слитые полипептиды cd40l-fc и способы их применения
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
JP2016523959A5 (OSRAM)
IL278014B2 (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
JP2017527272A5 (OSRAM)
JP2018514209A5 (OSRAM)